News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Tissue Repair and Wound Care Applications


7/25/2007 11:45:51 AM

MOUNTAINSIDE, N.J., July 25 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. , together with Michael Cohen and Jacob Cohen, today announced the filing of a provisional patent application for a newly discovered group of cellular derived biomaterials that appear to promote tissue repair in a variety of wound care applications. These new biomaterials are derived from the company's proprietary stem cell and progenitor cell lines.

Preclinical studies with these newly discovered biomaterials appear to enhance the rate of tissue repair and healing and of the strength of healed wounds. The Company believes that further research and development will clarify indications thus far that these biomaterials may be useful for a wide variety of acute and chronic wounds including but not limited to, burns, surgery related, and diabetes related.

Government Accounting Office (GAO) statistics show a tremendous need for wound care treatment. Each year, according to the GAO, approximately five million Americans suffer from chronic wounds caused by diabetes, circulatory problems and many other conditions. Other relevant statistics on wounds include: 1) 1.5 million people who will suffer from chronic wounds have diabetic ulcers; 2) 2.5 million people have pressure ulcers; 3) 1 million people have venous stasis (circulatory) ulcers; 4) 15 percent of all diabetics will develop chronic wounds; 5) Patients with diabetes have a 15-fold increase in the risk of amputation; 6) Approximately 60,000 diabetics will undergo amputation each year and wound care has grown to become a $2 billion market globally. National Stem Cell's work provides for wounds to heal faster and stronger.

National Stem Cell Holding, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. In addition to its work with stem cell therapeutics, the Company is also working to leverage its commercial infrastructure and product development capabilities of its wholly-owned subsidiary The Sperm Bank of NY. The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company is headquartered in Mountainside, NJ.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements, which include, but are not limited to statements regarding: the trademark application, the ability of the biomaterials to promote tissue repair and the variety of wound care applications. All of such forward-looking statements are not guarantees of future performance. They are based on management's current expectations and are subject to risks and uncertainties that are difficult to predict and generally beyond the control of the Company, and that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: the risk that the patent application will not be granted, the risk that the analysis of future data will not warrant continuation of development; the risk that the FDA, the institutional review boards for the clinical sites or the investigators may not agree with the Company's assessment of the results and may not permit future trials; the risk that concerns may arise from additional analysis or data; and the risk that the Company may encounter other unexpected hurdles. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. National Stem Cell Holding, Inc. does not undertake any obligation to update or revise any forward-looking statements, to reflect changes to management's expectations, change in events, conditions or circumstances after the date hereof, or the occurrence of or non-occurrence of any events, new information or otherwise.

National Stem Cell Holding, Inc.

CONTACT: Emily Rosenthal, General Council, +1-212-792-6160


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES